Today's Trend
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has attracted investor attention after raising its 2026 revenue outlook, receiving higher analyst forecasts, and reaching more than two-year highs. The news points to improving commercial expectations for its TIL cancer therapy, although the company remains unprofitable and some valuation signals are mixed.
- Higher revenue outlook supports the bull case. Iovance’s increased FY2026 revenue guidance is the main catalyst behind the recent advance, signaling stronger expectations for product demand and commercial execution. IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
- Analysts are improving earnings expectations. Zacks Research raised its FY2026 EPS forecast to a loss of $0.55 from $0.56, FY2027 to a loss of $0.39 from $0.44, and FY2028 to a loss of $0.03 from $0.07. Several quarterly estimates were also revised higher, with Q3 2028 projected at breakeven. HC Wainwright likewise raised its estimates, maintained a “Buy” rating, and kept a $20 price target. Analyst earnings estimates for Iovance Biotherapeutics
- Additional analyst support is helping sentiment. Wells Fargo increased its price target, while the broader consensus target was reported as rising 34.74% to $13.06. Zacks’ earnings-surprise methodology also identified IOVA as a stock investors should monitor for a potential earnings beat. Iovance Biotherapeutics Stock Gets Price Target Increase from Wells Fargo
- Management strengthened its medical leadership. Iovance appointed Noah Berkowitz, M.D., Ph.D., as chief medical officer, adding global drug-development experience in T-cell therapies. The appointment is strategically supportive but is unlikely to materially affect near-term results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
- Losses and valuation risks remain. Iovance is still expected to report a full-year loss, and the reported $13.06 consensus target is below the recent trading level. That gap could limit upside or increase volatility if revenue growth fails to meet elevated expectations.